Tag Archives: XEL

Hot Performing Stocks To Own Right Now

In Johnson & Johnson news, the stock is down 1.3% over the last five trading days, and that makes this the perfect time to buy this dividend aristocrat…

The pullback was caused by two analysts downgrading Johnson & Johnson (NYSE: JNJ) on July 21, but analysts simply don’t know how to value JNJ stock.

BTIG Research downgraded JNJ from “Neutral” to “Sell” because it doesn’t think Johnson & Johnson will be able to successfully execute its medical device acquisition.

Alembic Global Advisors downgraded the company from “Neutral” to “Underperforming” but didn’t release its rationale.

Hot Performing Stocks To Own Right Now: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Todd Campbell]

    Tesaro’s (NASDAQ:TSRO)ovarian cancer drug, niraparib, will begin competing for prescriptions earlier than expected. Niraparib, which will be sold under the brand name Zejula, notched FDA approval on Monday, more than three months ahead of its June 30 decision date. The early approval setsTesaro up for a fierce battle for market share withAstraZeneca (NYSE:AZN)and Clovis Oncology (NASDAQ:CLVS), both of which market drugs that work similarly to Zejula.

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

  • [By Ben Levisohn]

    Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:

Hot Performing Stocks To Own Right Now: JinkoSolar Holding Company Limited(JKS)

Advisors’ Opinion:

  • [By Lisa Levin]

    JinkoSolar Holding Co (NYSE: JKS) dropped 9.88% to $16.87 after the company announced the offering of 3,500,000 American Depositary Shares.

    Fuwei Films (Holdings) Co (NASDAQ: FFHL) dropped 9.66% to $1.30. Fuwei Films’ trailing-twelve-month ROE is -10.85%.

  • [By Elizabeth Balboa]

    First Solar, Inc (NASDAQ: FSLR) was trading down 3.7 percent Monday, while JA Solar Holdings Co., Ltd. (ADR) (NASDAQ: JASO) was down 0.8 percent, SunPower Corporation (NASDAQ: SPWR) 4.4 percent, Canadian Solar Inc. (NASDAQ: CSIQ) 5.2 percent and JinkoSolar Holding Co., Ltd. (NYSE: JKS) 4.4 percent.

  • [By Paul Ausick]

    But the real news is the near vertical trajectory in share prices for the two stocks. This could be another manifestation of the markets hunger for some momentum plays, as we noted earlier this morning the bump to share prices for both JinkoSolar Holding Co. Ltd. (NYSE: JKS) and Shutterstock Inc. (NASDAQ: SSTK), both of which held secondary share sales this morning.

  • [By Lisa Levin]

    In trading on Monday, energy shares fell by 0.59 percent. Meanwhile, top losers in the sector included JinkoSolar Holding Co., Ltd. (NYSE: JKS), down 8 percent, and Teekay Offshore Partners L.P. (NYSE: TOO) down 7 percent.

Hot Performing Stocks To Own Right Now: Xcel Energy Inc.(XEL)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Jefferies announced on Wednesday that it has raised its rating on Xcel Energy Inc (XEL).

    The firm has upgraded XEL from “Hold” to “Buy,” and has raised the company’s price target from $31 to $32.50. This new price target suggests a 15% upside from the stock’s current price of $27.72.

    Analyst Paul B. Fremont commented: “The stock is currently trading at an 8% P/E discount to our 2015E group average multiple.”

    “Despite a difficult political environment in Minnesota the company was able to achieve a reasonable outcome in its NSP-Minnesota rate case,” the analyst added.

    Looking forward, the firm has increased its FY2014 outlook from $1.95 to $2.00 per share.

    Xcel Energy shares were mostly flat during pre-market trading Wednesday. The stock has been mostly flat YTD.

financial markets

June 22, 2017: Here are four stocks trading with heavy volume among 106 equities making new 52-week lows in Thursday’s session. On the NYSE, advancers led decliners by nearly 3 to 2 and on the Nasdaq, advancers led decliners by about the same ratio.

The Hain Celestial Group Inc. (NASDAQ: HAIN) posted a new 52-week low of $31.70 on Thursday, down about 4.4% compared with Wednesday’s closing price of $33.16. The stock’s 52-week high is $56.99. Volume totaled more than 12.5 million shares, about 10 times the daily average of around 1.2 million. The organic food company said this morning that an accounting review has shown that the company does not need to change its accounting practices. Shares turned positive later in the day and are on track to close up about 1%.

DDR Corp. (NYSE: DDR) dropped about 3.2% Thursday to post a new 52-week low of $8.11 after closing at $8.38 on Wednesday. The stock’s 52-week high is $19.92. Volume of nearly 12 million was about 40% higher than the daily average. The company had no specific news.

financial markets: The Michaels Companies, Inc.(MIK)

Advisors’ Opinion:

  • [By Laurie Kulikowski]

    We rate MICHAELS COS INC as a Sell with a ratings score of D+. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. Among the areas we feel are negative, one of the most important has been weak operating cash flow. 

  • [By Jim Cramer]

    After a year of stock price fluctuations, the net result is that MIK’s price has not changed very much. Although its weak earnings growth may have played a role in this flat result, don’t lose sight of the fact that the performance of the overall market, as measured by the S&P 500 Index, was essentially similar. Turning toward the future, the fact that the stock has come down in price over the past year should not necessarily be interpreted as a negative; it could be one of the factors that may help make the stock attractive down the road. Right now, however, we believe that it is too soon to buy.

     

  • [By Jim Cramer]

    The company, on the basis of net income growth from the same quarter one year ago, has significantly outperformed against the S&P 500 and exceeded that of the Specialty Retail industry average. The net income increased by 20.0% when compared to the same quarter one year prior, going from $64.00 million to $76.80 million.

     

  • [By WWW.THESTREET.COM]

    Earnings of note in the coming week include Analogic (ALOG) and Ascena Retail (ASNA) on Monday; Bojangles (BOJA) , H&R Block (HRB) , and Dick’s Sporting Goods (DKS) , Michaels (MIK) , and Urban Outfitters (URBN) on Tuesday; Ciena (CIEN) , Bankrate (RATE) , Express (EXPR) , Vera Bradley (VRA) , and Bob Evans Farms (BOBE) on Wednesday; El Pollo Loco (LOCO) , Hugo Boss (BOSSY) , Party City (PRTY) , Signet Jewelers (SIG) , and Verifone Systems (PAY) on Thursday; and Kirkland’s (KIRK) , and Vail Resorts (MTN) on Friday.

  • [By JPMorgan]

    MIK’s results over the past year point to the company’s success in improving merchandising, marketing, and in-store execution plus the benefits of having a functioning e-commerce website. We believe part of the challenge for the bears is both a lack of appreciation for the category as well as missing the historical context of how leadership has evolved. Indeed, the difference in focus on "the front end" under CEO Chuck Rubin (who arrived in 2013) vs. a more process-oriented and margin-focused CEO prior to his arrival left a lot of impactful, low hanging fruit opportunities. Finally, while we acknowledge that longer term the sustainable comp is lower than the recent ~4% underlying trend, we point to the low volatility of sales, high cash generative nature of the business, barriers to entry (e.g., high SKU density, low inventory turns, lack of brands), and MIK’s market leadership as reasons why the multiple has the potential to expand over time (a la AZO). Balance sheet de-levering should also make the PE look increasingly cheap over time and transfer cash/value to equity holders. 

  • [By Jim Cramer]

    42.37% is the gross profit margin for MICHAELS COS INC which we consider to be strong. Regardless of MIK’s high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 6.57% trails the industry average.

    MICHAELS COS INC has improved earnings per share by 19.4% in the most recent quarter compared to the same quarter a year ago. This year, the market expects an improvement in earnings ($1.70 versus $1.04).

     

financial markets: Sage Therapeutics, Inc.(SAGE)

Advisors’ Opinion:

  • [By Lisa Levin]

    SAGE Therapeutics Inc (NASDAQ: SAGE) shares shot up 73 percent to $159.39 after the company disclosed that Phase 2 trial of SAGE-217 met its primary endpoint.

  • [By WWW.THESTREET.COM]

    Position: Long GLD small, bonds, SDS; short TLT small, SPY small .

  • [By Chris Lange]

    Shares of Sage Therapeutics Inc. (NASDAQ: SAGE) saw an incredible gain on Thursday after the firm announced positive top-line results from its midstage trial. Specifically, the firm reported results from its Phase 2 trial of Sage-217 for the treatment of moderate to severe major depressive disorder (MDD).

  • [By WWW.THESTREET.COM]

    The Good

    The market remains resistant (Rs over Ss and Ns). Brokerages, banks and insurance companies continue their league-leading strength. The Russell 2000 Index is up for the 15th consecutive day. Retail extends yesterday’s strength. Nordstrom (JWN) , Macy’s (M) , Best Buy (BBY) , Target (TGT) , Walmart (WMT) , Foot Locker (FL) and JCPenney (JCP) are strong. First day down for Amazon (AMZN) . Agricultural commodities are lackluster, but soybeans are up another up $0.05 today, up substantially for three days in a row. Speculative biotech (Sage (SAGE) , FibroGen (FGEN) , Acadia Pharmaceuticals (ACAD) and Aerie Pharmaceuticals  (AERI) ) stronger after recent weakness. Ag equipment up big time after the Deere (DE) beat.

    The Bad

financial markets: WildHorse Resource Development Corporation (WRD)

Advisors’ Opinion:

  • [By Paul Ausick]

    WildHorse Resource Development Corp. (NYSE: WRD) raised $413 million on the sale of $27.5 million at $15 per share, well below the expected range of $19 to $21. Shares popped just 0.4% for the day and closed the week down 0.9%.

financial markets: VEXIM EUR0.10 (VXMFF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    French medical device maker Vexim (OTC:VXMFF) contracted with an unnamed China lab to begin China registration studies for its vertebral fracture repair device, SpineJack庐. Vexim recently was granted patents for the device in China and Japan. SpineJack is an implant designed to repair a fractured vertebra and restore spinal cord balance. The 30 minute procedure is useful in 95% of vertebral fractures, according to Vexim. SpineJack was CE marked for EU use in 2010 and now is indicated for trauma and other vertebral fractures.

financial markets: Xcel Energy Inc.(XEL)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Jefferies announced on Wednesday that it has raised its rating on Xcel Energy Inc (XEL).

    The firm has upgraded XEL from “Hold” to “Buy,” and has raised the company’s price target from $31 to $32.50. This new price target suggests a 15% upside from the stock’s current price of $27.72.

    Analyst Paul B. Fremont commented: “The stock is currently trading at an 8% P/E discount to our 2015E group average multiple.”

    “Despite a difficult political environment in Minnesota the company was able to achieve a reasonable outcome in its NSP-Minnesota rate case,” the analyst added.

    Looking forward, the firm has increased its FY2014 outlook from $1.95 to $2.00 per share.

    Xcel Energy shares were mostly flat during pre-market trading Wednesday. The stock has been mostly flat YTD.

financial markets: Chiasma, Inc.(CHMA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Chiasma Inc (NASDAQ: CHMA) was down, falling around 13 percent to $9.51 ahead of the U.S. Food and Drug Administration’s decision on Friday to approve or reject the company’s therapy. The status of its oral treatment for acromegaly, a capsule known as Mycapssa, will be in focus on Friday. The Street’s biotechnology expert Adam Feuerstein stated that an investor source believes the FDA will reject Chiasma’s capsules because data from a single-arm study failed to demonstrate a clinically meaningful benefit among patients.

great stocks under 10

Wall Street could hardly be quieter, with large-cap stocks in their narrowest trading range since the 1960s as the CBOE Volatility Index (VIX) continues in its longest consecutive streak below 11.

The national psyche is obsessed with the cavalcade of political news out of Washington; largely ignoring market-specific events like chatter of an OPEC-Russia supply freeze extension of a bit of softness in the housing market. Despite this, Big Tech stocks remain well bid with a narrow group of all-stars pushing the Nasdaq to a new high.

In the end, the Dow Jones Industrial Average lost a fraction, the S&P 500 lost 0.1%, the Nasdaq Composite gained 0.3% and the Russell 2000 gained 0.1%. Treasury bonds were stronger, the dollar weakened again, gold gained 0.5% and crude oil lost 0.4% as the bounce from the supply freeze extension news from earlier in the week faded on realization it will only steepen OPEC’s market share loss to U.S. shale producers.

great stocks under 10: BanColombia S.A.(CIB)

Advisors’ Opinion:

  • [By Monica Gerson]

    Bancolombia SA (ADR) (NYSE: CIB) is expected to post its quarterly earnings at $0.77 per share on revenue of $945.66 million.

    Cellcom Israel Ltd. (NYSE: CEL) is estimated to post its earnings for the latest quarter.

  • [By Javier Hasse]

    Analysts at Credit Suisse downgraded shares of Bancolombia SA (ADR) (NYSE: CIB) from Outperform to Neutral, while boosting their price target from $38 to $40.

  • [By Lisa Levin]

    Foreign Regional Banks: This industry declined 2 percent by 11:00 am with Bancolombia SA (ADR) (NYSE: CIB) moving down 3.7 percent. Bancolombia’s PEG ratio is 4.51.

great stocks under 10: VEXIM EUR0.10 (VXMFF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    French medical device maker Vexim (OTC:VXMFF) contracted with an unnamed China lab to begin China registration studies for its vertebral fracture repair device, SpineJack庐. Vexim recently was granted patents for the device in China and Japan. SpineJack is an implant designed to repair a fractured vertebra and restore spinal cord balance. The 30 minute procedure is useful in 95% of vertebral fractures, according to Vexim. SpineJack was CE marked for EU use in 2010 and now is indicated for trauma and other vertebral fractures.

great stocks under 10: Big Lots, Inc.(BIG)

Advisors’ Opinion:

  • [By Lisa Levin]

    Big Lots, Inc. (NYSE: BIG) reported better-than-expected earnings for its third quarter, and raised its FY17 guidance.

    Big Lots posted quarterly earnings of $0.06 per share on revenue of $1.111 billion. However, analysts were expecting earnings of $0.04 per share on revenue of $1.12 billion. Its comparable store sales rose 1 percent during the quarter.

  • [By Peter Graham]

    A long term performance chart shows small cap off-price or value price retailers like Five Belowand Big Lots (NYSE: BIG) along with large capRoss Stores, Inc (NASDAQ: ROST) largely moving higher in positive territoryamidstvolatility:

  • [By Peter Graham]

    A long term performance chart shows small cap off-price or value price retailers like Five Belowand Big Lots (NYSE: BIG) along with large capRoss Stores, Inc (NASDAQ: ROST) largely moving into positive territory albeit with their share of volatility:

great stocks under 10: Teck Resources Ltd(TCK)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Stephens (Equal-Weight) and Citi (Sell) both downgraded Atwood Oceanics (NYSE: ATW).

    Sell-Side's Most Noteworthy Calls
    Investec downgraded Anheuser-Busch (NYSE: BUD) to Hold.
    Deutsche Bank downgraded Freeport McMoRan (NYSE: FCX) to Hold.
    Goldman Sachs upgraded Microsoft (NASDAQ: MSFT) to Buy.
    Barclays upgraded Teck Resources (NYSE: TCK) to Overweight.
    BTIG started Adobe (NASDAQ: ADBE) at Neutral.
    Deal Talk

    U.S. oil refiner Tesoro (NYSE: TSO) said it would buy Western Refining (NYSE: WNR) for $4.1 billion to add refineries in Texas, New Mexico and Minnesota. The combined company will have refining capacity of over 1.1 million barrels per day. Tesoro has refineries in California, Washington, Alaska, Utah and North Dakota.

great stocks under 10: Chipotle Mexican Grill Inc.(CMG)

Advisors’ Opinion:

  • [By Casey Wilson]

    Unfortunately, there were a lot of disappointing companies to choose from. We picked the worst of the worst. Check out our list of the most-hated companies of 2016…

    Most-Hated Companies 2016 No. 5: Chipotle Mexican Grill Inc. (NYSE: CMG)

    Chipotle’s problems all started in July 2015 with an E. coli outbreak…

  • [By Rick Munarriz]

    Just when you thought that a return to positive comps would spell an end to the giveaways thatChipotle Mexican Grill(NYSE:CMG)sprinkled through 2016, the former fast-casual darling is back with another online game where everybody’s a winner.

  • [By Peter Graham]

    Troubled mid cap restaurant stock Chipotle Mexican Grill, Inc (NYSE: CMG) reported Q2 2017 earnings after the market closed today. Revenue was up 17.1% to $1.17 billion driven by new restaurant openings (50 new restaurants were opened during the quarter and two were closed, bringing the total restaurant count to 2,339) and an 8.1% increase in comparable restaurant sales. Comparable restaurant sales improved primarily due to an increase in customer visits, along with an increase in average check as a result of a reduction in promotional activity. Food costs were 34.1% of revenue, a decrease of 10 basis points as compared to the second quarter of 2016 ashigher avocado costs were offset by lower costs from bringing the preparation of lettuce and bell peppers back intorestaurants, as well as the benefit of menu price increases in select restaurants in the second quarter of 2017, and a decrease in paper usage and costs. Net income increased 161% to $66.7 million.

  • [By Ben Levisohn]

    Chipotle Mexican Grill (CMG) soared to the top of the S&P 500 today after M Science, a data analytics firm, predicted better same-store sales.

    Getty Images

    Chipotle Mexican Grillgained 2.8% to $407.52 today, while the S&P 500 dropped 1.2% to 2,344.02.

    Bloomberg’s Craig Giammona and Leslie Patton have the details on the M Science report:

    Chipotle Mexican Grill Inc. shares rose the most in almost six weeks after data-analysis firm M Science predicted that first-quarter sales will easily beat Wall Streets estimates, bringing a ray of optimism to a chain battered by a food-safety crisis.

    The researcher studied same-store sales during February and the first 10 days of March, according to M Science Chief Executive Officer Michael Marrale. The firm made the call based on multiple data sets and proprietary models, he said.

    Chipotle Mexican Grill’s market capitalization rose to $12.9 billion today from $11.4 billion yesterday. It reported net income of $22.9 million on sales of $3.9 billion in 2016.

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, Chipotle Mexican Grill(NYSE:CMG) and iRobot (NASDAQ:IRBT) both enjoyed market-beating gains as investors reacted to fresh quarterly earnings reports.

  • [By The Ticker Tape]

    For more earnings coverage, check out what might be expected when McDonald's Corporation (NYSE: MCD) The Coca-Cola Co (NYSE: KO), and Chipotle Mexican Grill, Inc. (NYSE: CMG) report earnings tomorrow. Later in the week, tech titans Amazon.com, Inc. (NASDAQ: AMZN), Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL), Microsoft Corporation (NASDAQ: MSFT) and Intel Corporation (NASDAQ: INTC) report after market close on Thursday.

great stocks under 10: Xcel Energy Inc.(XEL)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Jefferies announced on Wednesday that it has raised its rating on Xcel Energy Inc (XEL).

    The firm has upgraded XEL from “Hold” to “Buy,” and has raised the company’s price target from $31 to $32.50. This new price target suggests a 15% upside from the stock’s current price of $27.72.

    Analyst Paul B. Fremont commented: “The stock is currently trading at an 8% P/E discount to our 2015E group average multiple.”

    “Despite a difficult political environment in Minnesota the company was able to achieve a reasonable outcome in its NSP-Minnesota rate case,” the analyst added.

    Looking forward, the firm has increased its FY2014 outlook from $1.95 to $2.00 per share.

    Xcel Energy shares were mostly flat during pre-market trading Wednesday. The stock has been mostly flat YTD.